Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Thursday

Viridian Therapeutics (NASDAQ:VRDN) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Viridian Therapeutics Stock Down 0.6%

Shares of NASDAQ VRDN opened at $28.11 on Thursday. The firm has a fifty day simple moving average of $31.55 and a two-hundred day simple moving average of $25.89. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $34.29. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $2.68 billion, a PE ratio of -9.31 and a beta of 0.98.

Analysts Set New Price Targets

VRDN has been the topic of several research reports. Royal Bank Of Canada lifted their price objective on Viridian Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Wednesday, January 21st. Truist Financial reduced their price target on Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Wedbush raised their price objective on Viridian Therapeutics from $42.00 to $47.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $40.00 target price on shares of Viridian Therapeutics in a research report on Thursday, November 6th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Viridian Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $42.64.

Insiders Place Their Bets

In related news, insider Jennifer Tousignant sold 2,272 shares of the firm’s stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $31.16, for a total transaction of $70,795.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.58% of the company’s stock.

Institutional Investors Weigh In On Viridian Therapeutics

Several institutional investors have recently modified their holdings of VRDN. MetLife Investment Management LLC boosted its holdings in shares of Viridian Therapeutics by 0.8% during the 4th quarter. MetLife Investment Management LLC now owns 43,985 shares of the company’s stock valued at $1,369,000 after acquiring an additional 356 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Viridian Therapeutics by 0.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,360 shares of the company’s stock valued at $4,337,000 after purchasing an additional 380 shares during the period. US Bancorp DE boosted its holdings in Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after purchasing an additional 463 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Viridian Therapeutics by 1.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after purchasing an additional 876 shares during the period. Finally, Virtus Investment Advisers LLC raised its stake in Viridian Therapeutics by 13.4% during the 4th quarter. Virtus Investment Advisers LLC now owns 8,233 shares of the company’s stock valued at $256,000 after buying an additional 971 shares during the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.